Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical

Posted by sai987 on May 28th, 2018

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment

Overview:

Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.

ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-respiratory-distress-syndrome-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:

By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Interferon Beta-1a
  • Imatinib
  • Sivelestat
  • L-Citrulline
  • Poractantalfa
  • Ganciclovir
  • Others

By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • AltorBioScience
  • Genentech, Inc.
  • Faron Pharmaceuticals Ltd.
  • AltorBioScience
  • Suntory Pharmaceutical
  • Eli Lilly and Company
  • Asklepion Pharmaceuticals, LLC
  • BioMarck Pharmaceuticals, Ltd.
  • Others

 

Space Analysis:

  • In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
  • In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)
Link To Directory
Top Searches - Trending Searches - New Articles - Top Articles - Trending Articles - Featured Articles - Top Members

Copyright 2019 Uberant.com
638,153 total articles and counting.